Contrary to conventional medical wisdom, metformin compares favorably with insulin for controlling blood sugar in A2 gestational diabetes—GD with elevated fasting blood sugar levels.
Contrary to conventional medical wisdom, metformin compares favorably with insulin for controlling blood sugar in A2 gestational diabetes-GD with elevated fasting blood sugar levels.
Researchers randomized women at less than 36 weeks' gestation to achieve normal blood sugar levels by either subcutaneous insulin injection (0.7 units) or 500 mg of metformin, with the goal of attaining postprandial blood glucose readings of less than 120 mg/dL and fasting blood sugars of between 60 and 90 mg/dL. Pregnant women were excluded from the study if they had conditions like insulin-dependent diabetes mellitus, chronic hypertension, or seizure disorders.
Thirty-one patients received insulin injection and 32 metformin. Those receiving the latter weighed about 30 lb more than the other group. Glucose levels were similar in each group and actually somewhat lower in the metformin group 2 hours after lunch (mean 106 vs. 112.5) and 2 hours after dinner (mean 108.1 vs. 109.2). There was little difference in abdominal delivery rates, shoulder dystocia, and postpartum hemorrhage and no differences in newborn statistics between the two groups, nor in birthweight, Apgar score at 5 minutes, or NICU admission.
Link between prenatal air pollution and reduced lung function in offspring reported
July 25th 2024Higher prenatal exposure to PM2.5 pollution is associated with reduced lung volume and airflow limitation in children, highlighting the critical impact of air pollution on in utero lung development.
Read More
Cut costs observed from out-of-home care in children with prenatal substance exposure
July 24th 2024A recent study reveals that while children exposed to maternal substance use face higher hospital costs up to age 20 years, out-of-home care significantly mitigates this financial burden.
Read More
Global progress in neonatal tetanus elimination from 2000 to 2022
July 18th 2024Incorporating maternal and neonatal tetanus elimination strategies into national immunization activities is crucial for sustaining elimination and reducing neonatal mortality worldwide, as highlighted by the latest CDC report.
Read More
PreTRM test shows efficacy in reducing severe neonatal morbidity and mortality
July 18th 2024The PreTRM test, a blood-based biomarker test for predicting preterm birth risk, has demonstrated significant efficacy in lowering severe neonatal morbidity and mortality, as reported by Sera Prognostics Inc.
Read More